1603 related articles for article (PubMed ID: 29444952)
21. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
Karaiskos I; Galani I; Souli M; Giamarellou H
Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
[TBL] [Abstract][Full Text] [Related]
22. Activity of Imipenem-Relebactam and Meropenem-Vaborbactam against Carbapenem-Resistant, SME-Producing Serratia marcescens.
Biagi M; Shajee A; Vialichka A; Jurkovic M; Tan X; Wenzler E
Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932381
[TBL] [Abstract][Full Text] [Related]
23. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
Zhang Y; Kashikar A; Bush K
J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
[TBL] [Abstract][Full Text] [Related]
24. Carbapenemase producing
Karaiskos I; Galani I; Papoutsaki V; Galani L; Giamarellou H
Expert Rev Anti Infect Ther; 2022 Jan; 20(1):53-69. PubMed ID: 34033499
[TBL] [Abstract][Full Text] [Related]
25. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
[TBL] [Abstract][Full Text] [Related]
26. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
[TBL] [Abstract][Full Text] [Related]
27. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.
Falagas ME; Karageorgopoulos DE; Nordmann P
Future Microbiol; 2011 Jun; 6(6):653-66. PubMed ID: 21707312
[TBL] [Abstract][Full Text] [Related]
29. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
Kanj SS; Bassetti M; Kiratisin P; Rodrigues C; Villegas MV; Yu Y; van Duin D
Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
[TBL] [Abstract][Full Text] [Related]
30. Activity of minocycline against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae clinical isolates, with comparison to doxycycline and tigecycline.
Chen A; Smith KP; Whitfield BA; Zucchi PC; Lasco TM; Bias TE; Kirby JE; Hirsch EB
Diagn Microbiol Infect Dis; 2017 Aug; 88(4):365-367. PubMed ID: 28535946
[TBL] [Abstract][Full Text] [Related]
31. Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae.
Papp-Wallace KM; Barnes MD; Alsop J; Taracila MA; Bethel CR; Becka SA; van Duin D; Kreiswirth BN; Kaye KS; Bonomo RA
Antimicrob Agents Chemother; 2018 Jun; 62(6):. PubMed ID: 29610205
[TBL] [Abstract][Full Text] [Related]
32. Meropenem-Vaborbactam versus Ceftazidime-Avibactam for Treatment of Carbapenem-Resistant
Ackley R; Roshdy D; Meredith J; Minor S; Anderson WE; Capraro GA; Polk C
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094128
[TBL] [Abstract][Full Text] [Related]
33. Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria.
D'Angelo RG; Johnson JK; Bork JT; Heil EL
Expert Opin Pharmacother; 2016; 17(7):953-67. PubMed ID: 26891857
[TBL] [Abstract][Full Text] [Related]
34. Infections Caused by Carbapenem-Resistant
Sheu CC; Chang YT; Lin SY; Chen YH; Hsueh PR
Front Microbiol; 2019; 10():80. PubMed ID: 30761114
[TBL] [Abstract][Full Text] [Related]
35. Rapid detection of resistance to carbapenems and cephalosporins in Enterobacteriaceae using liquid chromatography tandem mass spectrometry.
Tadros M; Goneau L; Romaschin A; Jarvis M; Matukas L
PLoS One; 2018; 13(11):e0206842. PubMed ID: 30412608
[TBL] [Abstract][Full Text] [Related]
36. Ceftazidime-Avibactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination for the Treatment of Resistant Gram-negative Organisms.
Sharma R; Park TE; Moy S
Clin Ther; 2016 Mar; 38(3):431-44. PubMed ID: 26948862
[TBL] [Abstract][Full Text] [Related]
37. Multidrug-Resistant and Carbapenemase-Producing
Tekele SG; Teklu DS; Legese MH; Weldehana DG; Belete MA; Tullu KD; Birru SK
Biomed Res Int; 2021; 2021():9999638. PubMed ID: 34195291
[TBL] [Abstract][Full Text] [Related]
38. Optimizing therapy of bloodstream infection due to extended-spectrum β-lactamase-producing Enterobacteriaceae.
Gudiol C; Cuervo G; Carratalà J
Curr Opin Crit Care; 2019 Oct; 25(5):438-448. PubMed ID: 31369411
[TBL] [Abstract][Full Text] [Related]
39. Extended spectrum β-lactamase producing enterobacteriaceae: carbapenem sparing options.
Aslan AT; Akova M
Expert Rev Anti Infect Ther; 2019 Dec; 17(12):969-981. PubMed ID: 31722185
[No Abstract] [Full Text] [Related]
40. The ideal patient profile for new beta-lactam/beta-lactamase inhibitors.
Montravers P; Bassetti M
Curr Opin Infect Dis; 2018 Dec; 31(6):587-593. PubMed ID: 30299359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]